CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	DeepHealth, Inc.	Total Radnet, Inc.'s Equity	Common Stock	Common Stock DeepHealth, Inc.	Additional Paid-In Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit	Noncontrolling Interests
Beginning balance (in shares) at Dec. 31, 2022				57,723,125
Beginning balance at Dec. 31, 2022	$ 491,452		$ 332,995	$ 6		$ 436,288	$ (20,677)	$ (82,622)	$ 158,457
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of options (in shares)				5,000
Issuance of common stock upon exercise of options	51		51			51
Issuance of common stock under the equity compensation plan (in shares)				1,065,877	20,085
Stock-based compensation expense	17,055		17,055			17,055
Issuance of common stock (in shares)				8,711,250
Issuance of common stock	246,202		246,202	$ 1		246,201
Issuance of common stock for sale of unregistered securities (in shares)				144,227
Issuance of common stock for sale of unregistered securities	4,000		4,000			4,000
Distributions paid to noncontrolling interests	(3,523)								(3,523)
Change in cumulative foreign currency translation adjustment	3,650		3,650				3,650
Change in fair value of cash flow hedge from prior periods reclassified to earnings	1,844		1,844				1,844
Other	(2)		(2)			(2)
Net (loss) income	275		(12,636)					(12,636)	12,911
Ending balance (in shares) at Jun. 30, 2023				67,669,564
Ending balance at Jun. 30, 2023	761,004		593,159	$ 7		703,593	(15,183)	(95,258)	167,845
Beginning balance (in shares) at Mar. 31, 2023				58,270,290
Beginning balance at Mar. 31, 2023	493,101		327,922	$ 6		448,522	(16,978)	(103,628)	165,179
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock under the equity compensation plan (in shares)				538,185	5,612
Stock-based compensation expense	4,870		4,870			4,870
Issuance of common stock (in shares)				8,711,250
Issuance of common stock	246,202		246,202	$ 1		246,201
Issuance of common stock for sale of unregistered securities (in shares)				144,227
Issuance of common stock for sale of unregistered securities	4,000		4,000			4,000
Distributions paid to noncontrolling interests	(3,523)		0						(3,523)
Change in cumulative foreign currency translation adjustment	873		873				873
Change in fair value of cash flow hedge from prior periods reclassified to earnings	922		922				922
Other	1		1					1
Net (loss) income	14,558		8,369					8,369	6,189
Ending balance (in shares) at Jun. 30, 2023				67,669,564
Ending balance at Jun. 30, 2023	$ 761,004		593,159	$ 7		703,593	(15,183)	(95,258)	167,845
Beginning balance (in shares) at Dec. 31, 2023	67,956,318			67,956,318
Beginning balance at Dec. 31, 2023	$ 813,359		630,695	$ 7		722,750	(12,484)	(79,578)	182,664
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of options (in shares)	60,306	9,377		60,605
Issuance of common stock upon exercise of options	$ 367		367			367
Issuance of common stock under the equity compensation plan (in shares)				657,887	9,377
Stock-based compensation expense	16,679		16,679			16,679
Issuance of common stock (in shares)				5,232,500
Issuance of common stock	218,385		218,385			218,385
Issuance of common stock in connection with acquisitions (in shares)				95,019
Issuance of common stock in connection with acquisitions	4,607		4,607			4,607
Forfeiture of restricted stock and share cancellation (in shares)				(43,664)
Forfeiture of restricted stock and share cancellation	(34)		(34)			(34)
Distributions paid to noncontrolling interests	(2,423)		0						(2,423)
Contributions from noncontrolling interests	11,601		11,601			11,601			0
Sale of economic interests in majority owned subsidiary, net of taxes	13,517								13,517
Change in cumulative foreign currency translation adjustment	(2,829)		(2,829)				(2,829)
Change in fair value of cash flow hedge from prior periods reclassified to earnings	7,256		7,256				7,256
Net (loss) income	$ 12,355		(5,761)					(5,761)	18,116
Ending balance (in shares) at Jun. 30, 2024	73,968,042			73,968,042
Ending balance at Jun. 30, 2024	$ 1,092,840		880,966	$ 7		974,355	(8,057)	(85,339)	211,874
Beginning balance (in shares) at Mar. 31, 2024				73,901,654
Beginning balance at Mar. 31, 2024	1,077,325		872,955	$ 7		969,248	(13,943)	(82,357)	204,370
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of options (in shares)				59,306
Issuance of common stock upon exercise of options	359		359			359
Issuance of common stock under the equity compensation plan (in shares)				41,120	4,984
Stock-based compensation expense	4,773		4,773			4,773
Forfeiture of restricted stock and share cancellation (in shares)				(39,022)
Forfeiture of restricted stock and share cancellation	(25)		(25)			(25)
Distributions paid to noncontrolling interests	(2,423)		0						(2,423)
Change in cumulative foreign currency translation adjustment	(631)		(631)				(631)
Change in fair value of cash flow hedge from prior periods reclassified to earnings	6,517		6,517				6,517
Net (loss) income	$ 6,945		(2,982)					(2,982)	9,927
Ending balance (in shares) at Jun. 30, 2024	73,968,042			73,968,042
Ending balance at Jun. 30, 2024	$ 1,092,840		$ 880,966	$ 7		$ 974,355	$ (8,057)	$ (85,339)	$ 211,874